Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Non-Current Debt (2020 - 2022)

SAB Biotherapeutics' Non-Current Debt history spans 2 years, with the latest figure at $541644.0 for Q4 2022.

  • For Q4 2022, Non-Current Debt changed N/A year-over-year to $541644.0; the TTM value through Dec 2022 reached $541644.0, changed N/A, while the annual FY2022 figure was $541644.0, N/A changed from the prior year.
  • Non-Current Debt reached $541644.0 in Q4 2022 per SABSW's latest filing, up from $172037.0 in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $541644.0 in Q4 2022 to a low of $172037.0 in Q4 2020.